Related Experiment Video
Updated: May 23, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Alzheimer's disease: pathogenesis and prevention.
Heiko Braak1, Kelly Del Tredici
1Clinical Neuroanatomy Section, Department of Neurology, Center for Biomedical Research, Ulm University, Germany. heiko.braak@uni-ulm.de
Summary
Alzheimer
Area of Science:
- Neuroscience
- Pathology
- Alzheimer's Disease Research
Background:
- Tau lesions, including pretangles and neurofibrillary tangles, are central to Alzheimer's disease pathogenesis.
- Pretangle formation is an early event, offering a window into disease initiation.
- Not all pretangles progress to neurofibrillary tangles, suggesting regulatory mechanisms.
Purpose of the Study:
- To investigate the role of oligodendrocyte maturation and brain myelination in Alzheimer's disease tau lesion development.
- To identify factors influencing the conversion of pretangles to neurofibrillary tangles.
Main Methods:
- The study proposes a theoretical framework based on existing literature and pathological observations.
- It analyzes the implications of oligodendrocyte developmental timing and protracted myelination in specific brain regions.
Main Results:
- Differences in early- versus late-maturing oligodendrocytes may influence tau pathology.
- Protracted myelination in late-developing brain areas could contribute to tau lesion progression.
Conclusions:
- Understanding oligodendrocyte differences and myelination timing is crucial for Alzheimer's disease.
- These insights may guide the development of novel preventative and therapeutic strategies for Alzheimer's disease.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...